TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30578550

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) using dense polytetrafluoroethylene (dPTFE) barrier membrane and mineralized cortical particulate freeze-dried bone allograft (FDBA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: GBR with membrane fixation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Estimated initial ridge width
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall GBR procedure
Number of subjects: 84
Study: 28742505

Group type: EXPERIMENTAL
Intervention: Hops dry extract (Melcalin hops); 0.2 gr capsules once daily for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo; 0.2 gr capsules once daily for 4 weeks
Number of subjects: 36
Study: 25488309

Group type: EXPERIMENTAL
Intervention: Fentanyl-first group (received fentanyl then midazolam)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Midazolam-first group (received midazolam then fentanyl)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 24612233

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22106952

Group type: EXPERIMENTAL
Intervention: Restorative home care
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 186
Study: 19317822

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 1041
Study: 16680561

Group type: COMPARATOR
Intervention: Desipramine (50 mg) alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Desipramine (50 mg) with cinacalcet (90 mg for 7 days)
Number of subjects: 17
Study: 15216539

Group type: EXPERIMENTAL
Intervention: S-Caine Peel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11436672

Group type: EXPERIMENTAL
Intervention: Active movement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Passive movement
Number of subjects: 39
Study: 9440757

Group type: EXPERIMENTAL
Intervention: 5-FU continuous intravenous infusion (CI)
Number of subjects: 1219

Group type: COMPARATOR
Intervention: 5-FU bolus administration
Number of subjects: 1219
Study: 7787380

Group type: EXPERIMENTAL
Intervention: Employment and retirement patterns, attitudes to work and retirement, involvement in leisure or recreational programmes; no specific intervention mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre‐retirement programmes including transition and choice‐making skills; no specific dosage or duration mentioned.
Number of subjects: 0
Study: 1969290

Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms kg‐1 before induction of anaesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fentanyl administered i.v. before propofol infusion
Number of subjects: 32
Study: 492905

Group type: EXPERIMENTAL
Intervention: Line-length change with tone (auditory input)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Line-length change without tone (no auditory input)
Number of subjects: 48
Study: 29909704

Group type: EXPERIMENTAL
Intervention: Ringer's solution plus oral fluids
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Dextrose solution 5% plus oral fluids
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oral fluids alone
Number of subjects: 201
Study: 30668631

Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Active support group (control)
Number of subjects: 57
Study: 28914272

Group type: EXPERIMENTAL
Intervention: Video intervention (n = 59)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care (n = 60)
Number of subjects: 119
Study: 25819269

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 24314359

Group type: EXPERIMENTAL
Intervention: TAK-085 2 g (2 g once daily)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: TAK-085 4 g (2 g twice daily)
Number of subjects: 503

Group type: COMPARATOR
Intervention: EPA-E 1.8 g (0.6 g three times daily)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: TAK-085 2 g
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: TAK-085 4 g
Number of subjects: 503

Group type: COMPARATOR
Intervention: EPA-E 1.8 g
Number of subjects: 503
Study: 21725957

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgical stripping
Number of subjects: 500
Study: 19463427

Group type: COMPARATOR
Intervention: CoStar (paclitaxel-eluting stent)
Number of subjects: 246

Group type: COMPARATOR
Intervention: SymBio (dual elution stent)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Corio (pimecrolimus-eluting stent)
Number of subjects: 246
Study: 17370494

Group type: EXPERIMENTAL
Intervention: O3 acupoint injection (30 microg/mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Danggui point injection
Number of subjects: 120
Study: 15049986

Group type: EXPERIMENTAL
Intervention: Doxazosin 1-8 mg once daily
Number of subjects: 210

Group type: COMPARATOR
Intervention: Alfuzosin 5-10 mg divided in two or three daily doses
Number of subjects: 210
Study: 11269737

Group type: EXPERIMENTAL
Intervention: 5-FU (370 mg/m2 i.v. over 1 h, days 2-6)
Number of subjects: 22
Study: 9517642

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 2 weeks
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at night for 2 weeks
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 9710032

Group type: EXPERIMENTAL
Intervention: MRS of abnormal white matter
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Histopathology findings
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Autopsy findings
Number of subjects: 5
Study: 2652864

Group type: EXPERIMENTAL
Intervention: Ketoconazole high dose (H.D.)
Number of subjects: 28
Study: 195190

Group type: EXPERIMENTAL
Intervention: CL 88,277 (250 mg, 1 ml administered three times a day plus one dose prior to challenge and for six consecutive post-challenge days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEG-400 (56% polyethylene glycol, solvent of CL 88,277)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CL 88,277
Number of subjects: 20

Group type: COMPARATOR
Intervention: PEG-400
Number of subjects: 20
Study: 31276672

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Linked color imaging (LCI)
Number of subjects: 272
Study: 29749716

Group type: EXPERIMENTAL
Intervention: Test dalfampridine tablet (generic formulation)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Branded dalfampridine tablet (reference formulation)
Number of subjects: 27
Study: 28829368

Group type: EXPERIMENTAL
Intervention: 500 mg of grape and apple polyphenols
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25651247

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700
Study: 23780354

Group type: EXPERIMENTAL
Intervention: OZ‐PG: ozonized propylene glycol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CH/CPMC: calcium hydroxide/camphorated paramonochlorophenol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OZ‐PG/CH: ozonized PG/CH
Number of subjects: 50

Group type: COMPARATOR
Intervention: PC: positive control group (no medication)
Number of subjects: 50

Group type: COMPARATOR
Intervention: NC: negative control group (no contamination)
Number of subjects: 50
Study: 21669376

Group type: EXPERIMENTAL
Intervention: Internet-based COPD population screener (COPD-PS)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Paper-and-pencil COPD population screener (COPD-PS)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Internet-based COPD-PS
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Paper-and-pencil COPD-PS
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Subgroup analyses on smoking status, presence of COPD, and shortness of breath
Number of subjects: 1006
Study: 19707999

Group type: EXPERIMENTAL
Intervention: Geriatric psychiatry unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: General psychiatry unit
Number of subjects: 0
Study: 16681659

Group type: EXPERIMENTAL
Intervention: Punch incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Elliptical excision
Number of subjects: 60
Study: 14975461

Group type: EXPERIMENTAL
Intervention: Combination therapy of half-dose reteplase and abciximab
Number of subjects: 2633

Group type: COMPARATOR
Intervention: Reteplase
Number of subjects: 2633
Study: 11725230

Group type: EXPERIMENTAL
Intervention: Surgical treatment (lumbar fusion)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Nonsurgical treatment (physical therapy)
Number of subjects: 294
Study: 9387956

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Plethysmography
Number of subjects: 61
Study: 8204228

Group type: EXPERIMENTAL
Intervention: Chronic calcium channel blockers
Number of subjects: 36

Group type: COMPARATOR
Intervention: No calcium channel blockers
Number of subjects: 36
Study: 3144169

Group type: EXPERIMENTAL
Intervention: Oral encainide (75 to 200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral quinidine (1,200 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 50
Study: 30934894

Group type: EXPERIMENTAL
Intervention: Marine n-3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Soybean oil placebo
Number of subjects: 102
Study: 28187222

Group type: EXPERIMENTAL
Intervention: 50 µg/wk 25‐hydroxyvitamin‐D3
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 150 µg/wk vitamin D3
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin‐D3 supplementation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control cells (not specified dosage)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Adrenaline stimulation
Number of subjects: 121
Study: 25287737

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 1944

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Regadenoson and Adenosine
Number of subjects: 1944
Study: 23881439

Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg/week) and calcium lactate (600 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium lactate (600 mg/day)
Number of subjects: 50
Study: 21809909

Group type: EXPERIMENTAL
Intervention: Obese patients with COPD
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Overweight patients with COPD
Number of subjects: 364

Group type: COMPARATOR
Intervention: Normal weight patients with COPD
Number of subjects: 364
Study: 19808656

Group type: EXPERIMENTAL
Intervention: Intravenous fructose (0.5 g/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous glucose (0.5 g/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 6
Study: 17015282

Group type: EXPERIMENTAL
Intervention: Polyphenolic extract of pine bark Pycnogenol (Pyc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15799911

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency ablation (n=77)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (n=13)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amiodarone therapy for 3 months post-surgery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with small preoperative left atrial diameters (<56 mm)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with large preoperative left atrial diameters (>=56 mm)
Number of subjects: 90
Study: 11055218

Group type: EXPERIMENTAL
Intervention: Therapeutic complex including vitrectomy with ozonized normal saline
Number of subjects: 55

Group type: COMPARATOR
Intervention: Vitrectomy with intravitreal administration of 0.4 mg gentamicin
Number of subjects: 55
Study: 9752242

Group type: EXPERIMENTAL
Intervention: Suction endotracheal catheters numbers 12, 14, and 16
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suction endotracheal catheters numbers 12 and 14
Number of subjects: 0
Study: 8360731

Group type: EXPERIMENTAL
Intervention: Hypothermia (32-33 degrees C for 24 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normothermia (37-38 degrees C)
Number of subjects: 40
Study: 3517241

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Doxorubicin and Mitoxantrone
Number of subjects: 90
Study: 30225665

Group type: EXPERIMENTAL
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:1 for the first hour followed by 1:2 (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:2 for the first hour followed by 1:1 (group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inspiratory to expiratory time ratio (I:E) of 1:2
Number of subjects: 32
Study: 29734548

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal glycemic index diet
Number of subjects: 37
Study: 24534402

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study: 23377509

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20584771

Group type: EXPERIMENTAL
Intervention: Schizophrenia (SCZ)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study: 17583431

Group type: EXPERIMENTAL
Intervention: Epidural ketamine and bupivacaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline and bupivacaine
Number of subjects: 53
Study: 16154062

Group type: EXPERIMENTAL
Intervention: Warm compresses to the perineal area
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Massage with lubricant
Number of subjects: 1211

Group type: COMPARATOR
Intervention: No touching of the perineum until crowning
Number of subjects: 1211
Study: 12814846

Group type: EXPERIMENTAL
Intervention: Coping-oriented therapy approach
Number of subjects: 0
Study: 10227413

Group type: EXPERIMENTAL
Intervention: Regular administration of antihypertensive medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening procedure using conditional rules
Number of subjects: 0
Study: 8707278

Group type: EXPERIMENTAL
Intervention: Patients who remained HBeAg positive with normal aminotransferase levels (Group I)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients who remained HBeAg positive with elevated aminotransferase levels (Group II)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Patients who cleared HBeAg (Group III)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Interferon treated patients
Number of subjects: 55

Group type: COMPARATOR
Intervention: Interferon responders
Number of subjects: 55
Study: 1909218

Group type: EXPERIMENTAL
Intervention: APSAC (30 units over 5 minutes)
Number of subjects: 183

Group type: COMPARATOR
Intervention: rt‐PA (100 mg over a 3‐hour period)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 183

Group type: COMPARATOR
Intervention: rt‐PA
Number of subjects: 183
Study: 6340977

Group type: EXPERIMENTAL
Intervention: 1 mg loprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30593884

Group type: EXPERIMENTAL
Intervention: Patient-completed Decision Support Tool (DST) for mental health care, including feedback on DST responses, treatment priorities, motivation assessment, and severity-matched treatment recommendations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual GP care plus attention control (comparison arm).
Number of subjects: 0
Study: 28570603

Group type: EXPERIMENTAL
Intervention: Ty21a vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-vaccinated control
Number of subjects: 20
Study: 25078946

Group type: EXPERIMENTAL
Intervention: Music intervention (experimental group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Nonmusic control group
Number of subjects: 97
Study: 24190345

Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 34
Study: 22492501

Group type: EXPERIMENTAL
Intervention: synthetic human PTH 1‐34 (hPTH 1‐34), injected two to three times daily for 18 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: synthetic human PTH 1‐34 (hPTH 1‐34)
Number of subjects: 5
Study: 19284064

Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 96
Study: 17202798

Group type: EXPERIMENTAL
Intervention: Propofol (induction 1.5 mg/kg, maintenance 1.5 mg kg(‐1) h(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam (induction 0.5 mg/kg, maintenance 0.1 mg kg(‐1) h(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups received fentanyl (induction 20 mug/kg, maintenance 10 microg kg(‐1))
Number of subjects: 20
Study: 15933272

Group type: EXPERIMENTAL
Intervention: Toileting and walking assistance provided by research staff; intervention duration: 8 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study: 15131518

Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 324

Group type: COMPARATOR
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 324
Study: 10573224

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with dihaematoporphyrin ether and argon dye laser photoradiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nd‐YAG laser resection
Number of subjects: 31
Study: 8751845

Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Integrilin
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: tirofiban (Aggrastat)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa blockade
Number of subjects: 3

Group type: COMPARATOR
Intervention: Standard patient care algorithms
Number of subjects: 3
Study: 1835624

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 122

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 122
Study: 6753120

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30474277

Group type: EXPERIMENTAL
Intervention: Temperature at 26°C
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Temperature at 30°C
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Temperature at 33°C
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Temperature at 37°C
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Increasing temperature (26°C to 37°C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Increasing temperature
Number of subjects: 32
Study: 28255849

Group type: EXPERIMENTAL
Intervention: Cladribine (CdA) as a single agent or in combination with interferon (IFN) β‐1a
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cladribine (CdA)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Cladribine (CdA) with coadministration of interferon (IFN) β‐1a
Number of subjects: 173
Study: 26096249

Group type: EXPERIMENTAL
Intervention: OneShape Endodontic File no.: 25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: WaveOne Endodontic File no.: 25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reciproc Endodontic File no.: 25
Number of subjects: 50
Study: 23432142

Group type: EXPERIMENTAL
Intervention: Omalizumab 75 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 21333265

Group type: EXPERIMENTAL
Intervention: Ocular Surface Thermographer measurements after 10 seconds of eye opening
Number of subjects: 60
Study: 19167081

Group type: EXPERIMENTAL
Intervention: 1% atropine eyedrops once nightly for 2 years
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (vehicle) eyedrops once nightly for 2 years
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 1% atropine eyedrops
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (vehicle) eyedrops
Number of subjects: 400
Study: 16913434

Group type: EXPERIMENTAL
Intervention: 5‐HT at 1,000 micromol/L
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5‐HT at 0.1 micromol/L
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 12
Study: 12773363

Group type: EXPERIMENTAL
Intervention: 6 sessions provided to couples together (n = 81)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: The same intervention provided to the woman alone (n = 73)
Number of subjects: 217

Group type: COMPARATOR
Intervention: 1-session control condition provided to the woman alone (n = 63)
Number of subjects: 217
Study: 11132390

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae (0.1 mL)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo (0.1 mL tetanus toxoid)
Number of subjects: 204
Study: 9061219

Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisolone/day for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg oral prednisolone/day for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3.2 mg inhaled budesonide/day for 2 weeks
Number of subjects: 30